Search results
4 days ago · We recently sat down with Scott Brinkman, the Associate Director of Global Security at Exact Sciences Corporation to discuss the approach his team takes to protective intelligence, threat assessment and how his corporate security program differs within a fast-moving biotech company.
Jun 27, 2024 · Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype Dx, its...
- 1.64
- 1.30
- −7.24
1 day ago · Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.
5 days ago · LOUIS, July 01, 2024 -- ( BUSINESS WIRE )--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, filed a lawsuit...
3 days ago · 15 analysts have issued 1-year target prices for Exact Sciences' stock. Their EXAS share price targets range from $70.00 to $121.00. On average, they predict the company's share price to reach $86.80 in the next twelve months. This suggests a possible upside of 101.0% from the stock's current price.
- (608) 284-5700
- 5505 ENDEAVOR LANE, MADISON WI, 53719
- meganjones@exactsciences.com
3 days ago · The medical research company reported ($0.50) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.50). The firm had revenue of $637.52 million for the quarter, compared to analyst estimates of $624.95 million.
3 days ago · Detailed annual and quarterly income statement for Exact Sciences (EXAS). See many years of revenue, expenses and profits or losses.
